Search
P2Y12-receptor inhibitor
Notes:
- prasugrel & ticagrelor more potent antiplatelet agents than clopidogrel & superior in preventing ischemic events, at the cost of increased risk of bleeding [3]
- genetic testing may provide some information on risk of mbleeding [3]
- genotype-guided dual antiplatelet therapy no better than standard clopidogrel-low-dose aspirin after percutaneous coronary intervention [4]
Interactions
drug interactions
drug adverse effects (more general classes)
Related
P2Y12 purinoceptor; P2Y purinoceptor 12; P2Y12; P2Y12 platelet ADP receptor; P2Y(ADP); ADP-glucose receptor; ADP receptor P2Y12; ADPG-R; P2Y(AC); P2Y(cyc); P2T(AC); SP1999 (P2RY12, HORK3)
Specific
clopidogrel (Plavix)
prasugrel (Effient)
ticagrelor (Brilinta)
General
antiplatelet agent
receptor antagonist
Properties
INHIBITS: P2Y12 purinoceptor
References
- Brilakis ES et al.
Medical management after coronary stent implantation: A review.
JAMA 2013 Jul 10; 310:189
PMID: 23839753
- Bellemain-Appaix A et al
Reappraisal of thienopyridine pretreatment in patients with
non-ST elevation acute coronary syndrome: a systematic review
and meta-analysis.
BMJ 2014;349:g6269
PMID: 25954988
http://www.bmj.com/content/349/bmj.g6269
- Susman E.
Genetic Testing Aids in Anticoagulant Selection in ACS.
Personalized approach tied to clinically meaningful reduction
in ischemic and bleeding events.
MedPage Today. March 12, 2018
https://www.medpagetoday.com/meetingcoverage/acc/71722
- Ardissino D, et al
A prospective, randomised, multicentre study of a
pharmacogenomic approach to the selection of antiplatelet
therapy in acute coronary syndromes.
American College of Cardiology (ACC) 2018;
Abstract 18-LB-18910-ACC.
- Notarangelo FM, Maglietta G, Bevilacqua P, et al
Pharmacogenomic approach to selecting antiplatelet therapy in
acute coronary syndromes: PHARMCLO trial.
J Am Coll Cardiol. March 2018
PMID: 29540324
http://www.onlinejacc.org/content/early/2018/02/23/j.jacc.2018.02.029
- Pereira NL et al.
Effect of genotype-guided oral P2Y12 inhibitor selection vs
conventional clopidogrel therapy on ischemic outcomes after
percutaneous coronary intervention: The TAILOR-PC randomized
clinical trial.
JAMA 2020 Aug 25; 324:761.
PMID: 32840598
https://jamanetwork.com/journals/jama/fullarticle/2769725